HC Wainwright restated their buy rating on shares of InflaRx (NASDAQ:IFRX - Free Report) in a research note released on Friday, Marketbeat.com reports. The firm currently has a $8.00 price objective on the stock.
InflaRx Price Performance
Shares of IFRX stock traded up $0.07 during mid-day trading on Friday, hitting $1.35. The company had a trading volume of 285,649 shares, compared to its average volume of 214,574. The stock's 50 day moving average price is $1.92 and its 200-day moving average price is $1.90. InflaRx has a 52-week low of $1.13 and a 52-week high of $2.82. The company has a market capitalization of $90.63 million, a P/E ratio of -1.25 and a beta of 1.98.
InflaRx (NASDAQ:IFRX - Get Free Report) last announced its quarterly earnings results on Thursday, March 20th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.18. InflaRx had a negative net margin of 33,362.70% and a negative return on equity of 65.98%. On average, equities research analysts expect that InflaRx will post -1.04 earnings per share for the current year.
Institutional Trading of InflaRx
A number of large investors have recently added to or reduced their stakes in the company. Two Sigma Securities LLC purchased a new position in shares of InflaRx in the fourth quarter valued at $28,000. Walleye Capital LLC bought a new position in InflaRx during the fourth quarter valued at $51,000. Cubist Systematic Strategies LLC purchased a new position in shares of InflaRx in the 4th quarter worth $55,000. Geode Capital Management LLC increased its holdings in shares of InflaRx by 32.8% in the 4th quarter. Geode Capital Management LLC now owns 48,136 shares of the company's stock worth $119,000 after buying an additional 11,900 shares during the last quarter. Finally, Commonwealth Equity Services LLC raised its position in shares of InflaRx by 20.5% during the 4th quarter. Commonwealth Equity Services LLC now owns 111,500 shares of the company's stock valued at $275,000 after buying an additional 19,000 shares in the last quarter. Institutional investors own 42.39% of the company's stock.
About InflaRx
(
Get Free Report)
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.
Read More
Before you consider InflaRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InflaRx wasn't on the list.
While InflaRx currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
